Alnylam Pharmaceuticals’ (ALNY) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a report issued on Monday,Benzinga reports. HC Wainwright currently has a $455.00 price target on the biopharmaceutical company’s stock.

Several other research firms have also commented on ALNY. Royal Bank Of Canada decreased their price target on shares of Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating for the company in a research report on Friday, July 31st. Barclays lowered their price target on Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating for the company in a research report on Monday, August 3rd. Jefferies Financial Group lifted their price objective on shares of Alnylam Pharmaceuticals from $230.00 to $260.00 and gave the company a “hold” rating in a research note on Tuesday, September 8th. Needham & Company LLC lowered their target price on Alnylam Pharmaceuticals from $510.00 to $357.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Finally, Wall Street Zen downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $367.20.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock opened at $244.32 on Monday. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75. The stock has a fifty day simple moving average of $246.41 and a two-hundred day simple moving average of $285.10. The stock has a market capitalization of $32.69 billion, a price-to-earnings ratio of 45.41 and a beta of 0.31. Alnylam Pharmaceuticals has a twelve month low of $197.81 and a twelve month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The company had revenue of $1.29 billion during the quarter, compared to analyst estimates of $1.32 billion. During the same period in the prior year, the firm earned ($0.51) earnings per share. The firm’s revenue for the quarter was up 66.9% compared to the same quarter last year. On average, analysts predict that Alnylam Pharmaceuticals will post 6.71 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. MV Capital Management Inc. purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $25,000. Manchester Capital Management LLC increased its holdings in shares of Alnylam Pharmaceuticals by 600.0% during the 4th quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 72 shares during the last quarter. Leonteq Securities AG acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter worth $42,000. Titan Wealth CI Ltd acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $42,000. Finally, SHP Wealth Management acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $43,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi) technology. RNAi therapies are designed to silence specific genes involved in disease, offering a way to target conditions that may be difficult to treat with conventional drug approaches. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Amvuttra (vutrisiran).